M&A / Deals Halozyme and Vertex sign deal for Hypercon technology Pharmaceutical Business ReviewVertex has licensed the technology for use in up to three drug targets, as part of the agreement.M&A / DealsRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaceutical Business Review Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. M&A / DealsRead full story Post navigation Previous: Gilead continues M&A surge with $3.1B deal for ADC specialist TubulisNext: RoosterBio and MineBio team up to expand MSC solutions access in China Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
